Microgynon 30

Ethinylestradiol, the active ingredient in Microgynon 30, is a combined oral contraceptive presented as a 30 µg ethinylestradiol / 150 µg levonorgestrel tablet for oral use. It works to prevent pregnancy and can also be used to regulate menstrual cycles in women of reproductive age. The formulation combines a synthetic estrogen with a progestogen to provide reliable cycle control.

GNH USA supplies Microgynon 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon 30, a combined oral contraceptive, is indicated for hormonal regulation of the reproductive system.

- Prevention of pregnancy: provides reliable contraceptive protection when taken as directed. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns. - Management of dysmenorrhea: can reduce menstrual pain associated with irregular cycles.

Microgynon 30 may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset, especially when starting therapy. - Headache: transient tension‑type headaches. - Breast tenderness: mild discomfort or swelling. - Spotting or breakthrough bleeding: irregular bleeding during the first cycles.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Hepatic adenoma: benign liver tumor, reported rarely. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Microgynon 30, clinicians should consider several safety precautions. - Assess cardiovascular risk: avoid in women with history of thromboembolic disorders. - Screen for smoking status: contraindicated in smokers over 35 years. - Evaluate liver function: use with caution in hepatic impairment. - Consider migraine history: avoid in patients with migraine with aura. - Review medication list: potential interactions may reduce efficacy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Microgynon 30 can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Rifampicin or other strong CYP3A4 inducers: can lead to contraceptive failure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone levels, raising risk of side effects. - Antiretroviral protease inhibitors (e.g., ritonavir): can affect hormone metabolism, requiring monitoring. - St. John’s wort: herbal inducer that may lower contraceptive effectiveness.